« Return to News | Clinical Intelligence

Jennerex enrolls first patient in phase IIb liver cancer trial

Friday, November 4, 2011 11:33 AM
Jennerex has initiated enrollment and the first patient has
been randomized in a phase IIb clinical trial called TRAVERSE.  The trial
is evaluating the use of JX-594 to treat patients with advanced liver
cancer, also known as hepatocellular carcinoma (HCC), who failed prior
therapy with sorafenib (NexavarR), the only approved drug for advanced
HCC.  In addition, Jennerex earned a milestone payment from its
development and commercialization partner, Transgene, based on the
randomization of the first patient in the TRAVERSE clinical trial.

The TRAVERSE phase IIb clinical trial is designed to enroll 120 patients
with advanced liver cancer who have failed sorafenib therapy. The
randomized study will be conducted at approximately 45 sites worldwide
including North America, South Korea, Taiwan, Hong Kong, and Europe. The
primary objective of the trial is to determine the overall survival
benefit for patients receiving JX-594 with best supportive care, compared
to best supportive care alone in patients with refractory advanced liver
cancer.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.